Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Weldon Mauney

Neurology with Special Qualifications in Child Neurology Gulf Breeze, FL Medical Doctor

NPI 1396915898 CMS profile 244589

400 Gulf Breeze Pkwy Ste 300, Gulf Breeze, FL 32561

Open in the dashboard

General payments

$7,523

221 records reported · program years 2019–2025

Research payments

$7,171

Paid to them · 2 records reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Research they led as principal investigator

$1,279,758 paid to institutions, not to them · program years 2019–2025

Through program year 2025, Weldon Mauney of Gulf Breeze, FL is reported in the CMS Open Payments database as having received $7,523 across 221 general payments and $7,171 in research payments paid to them. Separately, studies naming them as principal investigator received $1,279,758 in research payments, paid to institutions rather than to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.

General payments for this record sit in the 85th percentile of Neurology with Special Qualifications in Child Neurology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

8 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $1,166 47
2025 Research $7,171 2
2024 General $3,382 62
2023 General $1,124 44
2022 General $816 37
2021 General $453 10
2020 General $164 6
2019 General $418 15

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Weldon Mauney
  • Neurology with Special Qualifications in Child Neurology median
  • Middle half of Neurology with Special Qualifications in Child Neurology
  • National median

In program year 2025, general payments to Weldon Mauney were reported at $1,166. Among 1,228 Neurology with Special Qualifications in Child Neurology profiles paid that year, the median was $276 and the middle half received between $87 and $1,522.

Show as a table
Year Weldon Mauney Neurology with Special Qualifications in Child Neurology median Middle half National median
2019 $418 $262 $68–$1,313 $163
2020 $164 $188 $46–$1,222 $114
2021 $453 $183 $45–$1,356 $132
2022 $816 $229 $72–$1,177 $149
2023 $1,124 $269 $93–$1,195 $160
2024 $3,382 $300 $98–$1,428 $164
2025 $1,166 $276 $87–$1,522 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. H. Lundbeck A S $1,951 4 payments
  2. UCB, Inc. $1,492 66 payments
  3. Jazz Pharmaceuticals Inc. $456 16 payments
  4. Merz Pharmaceuticals, LLC $326 10 payments
  5. ACADIA Pharmaceuticals Inc $278 11 payments
  6. LivaNova USA, Inc. $277 10 payments
  7. Eisai Inc. $265 14 payments
  8. Neurelis, Inc. $246 6 payments
  9. Biogen, Inc. $239 11 payments
  10. Marinus Pharmaceuticals, Inc. $239 5 payments
  11. Other $1,754 68 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $5,555 216 payments
  2. Travel and Lodging $1,951 4 payments
  3. Education $17 1 payment
Products named General payments · program years 2019–2025
  1. Fintepla $804 34 payments
  2. Epidiolex $561 17 payments
  3. Briviact $438 22 payments
  4. DAYBUE $278 11 payments
  5. Fycompa Neurology $265 14 payments
  6. VALTOCO $246 6 payments
  7. SPINRAZA $239 11 payments
  8. ZTALMY $239 5 payments
  9. FYCOMPA Neurology $230 11 payments
  10. Xeomin $215 7 payments
  11. Other $1,909 81 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Research payments came from Research payments · program years 2019–2025
  1. Eli Lilly and Company $7,094 1 payment
  2. Amgen Inc. $77 1 payment

Billing to Medicare

Part B · data year 2024 · 18 billing codes

Paid by Medicare

$111,773

Of which drugs: $91,715

Medicare patients

38

Average age 52

Services billed

13,526

16 women, 22 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 45%
Arthritis 34%
Heart failure 0%
Alzheimer's or dementia 0%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Injection, onabotulinumtoxina, 1 unit J0585 Office 17 11,175 $54,573
Injection, baclofen, 10 mg J0475 Office 13 174 $23,928

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 13 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
FYCOMPA
  • CATALYST PHARMACEUTICALS, INC. $165
$165 — —
Fintepla
  • UCB, Inc. $141
$141 — —
Epidiolex
  • JAZZ PHARMACEUTICALS INC. $132
$132 — —
DAYBUE
  • ACADIA Pharmaceuticals Inc $130
$130 — —
DIACOMIT
  • BIOCODEX, INC. $111
$111 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 13 in the dashboard with a free account

Records

223 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Neurology with Special Qualifications in Child Neurology in Florida

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record